Buy & Sell D Wave Quantum Inc (QBTS) – D Wave Quantum Inc Price Today
Aura AI Summary
Key Stats
- $8.84BMarket Cap
- TechnologySector
- -31.85%3M Drawdown
- $8.29BEnterprise Value
- -Dividend Yield
- 11 daysTypical Hold Time
D Wave Quantum Inc (QBTS) is currently valued at a market capitalization of $8.84B, with an enterprise value of $8.29B. Over the past 52 weeks, D Wave Quantum Inc has traded between a low of $12.98 and a high of $44.78, highlighting its annual price range. Over the past three months, D Wave Quantum Inc has recorded a drawdown of -31.85%, reflecting recent price volatility. On average, investors hold D Wave Quantum Inc for approximately 11 days, indicating typical investor behavior on the platform.
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Most Recent News
Cyabra inks $500K+ deal to fight online hate with AI-powered disinformation detection for global research institute
Cyabra, an AI-driven disinformation intelligence company, has secured a contract worth over $500,000 to provide its technology to a leading international research institute focused on tracking global hate speech. The platform will help identify coord...

Ormat launches Ormega100, the largest binary geothermal unit, to boost Enhanced Geothermal System deployment.
Ormat Technologies introduced the Ormega100, the industry's largest binary power generation unit delivering 100 MW output, designed to accelerate commercialization and scaling of Enhanced Geothermal Systems (EGS). With 60 years of expertise and exten...

ADARx to present Phase 1/2 data on Onvuzosiran for hereditary angioedema at 2026 EAACI Congress
ADARx Pharmaceuticals announced it will present Phase 1/2 clinical data for Onvuzosiran, an RNA therapy for hereditary angioedema (HAE), at the 2026 EAACI Congress in Istanbul. Onvuzosiran targets plasma prekallikrein to prevent swelling attacks by r...
